NCT01570699View on ClinicalTrials.gov

Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients

CompletedOBSERVATIONAL
Enrollment

87

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Opioid-related DisordersOpiate DependenceOpiate AddictionOpiate Abuse
Interventions
GENETIC

COMT polymorphism

The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity

Trial Locations (1)

75010

Espace Murger, Consultation toxicomanie, Fernand-Widal Hospital (AP-HP), Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01570699 - Variation of COMT Val158Met Polymorphism Between COM-ON Patients and METHADOSE Patients | Biotech Hunter | Biotech Hunter